Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Instil Bio Inc. (TIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: TIL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $95.75
1 Year Target Price $95.75
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 248.31% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 174.03M USD | Price to earnings Ratio - | 1Y Target Price 95.75 |
Price to earnings Ratio - | 1Y Target Price 95.75 | ||
Volume (30-day avg) 4 | Beta 2.18 | 52 Weeks Range 10.80 - 72.87 | Updated Date 09/16/2025 |
52 Weeks Range 10.80 - 72.87 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.86% | Return on Equity (TTM) -51.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155751255 | Price to Sales(TTM) 55329.79 |
Enterprise Value 155751255 | Price to Sales(TTM) 55329.79 | ||
Enterprise Value to Revenue 43213.95 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 6750720 | Shares Floating 3308053 |
Shares Outstanding 6750720 | Shares Floating 3308053 | ||
Percent Insiders 6.32 | Percent Institutions 69.62 |
Upturn AI SWOT
Instil Bio Inc.
Company Overview
History and Background
Instil Bio Inc. is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer. Founded in 2018, the company aims to utilize its cell therapy expertise to create and deliver novel treatments for patients with solid tumors.
Core Business Areas
- Tumor-Infiltrating Lymphocyte (TIL) Therapies: Instil Bio is focused on developing and commercializing TIL therapies, which involve using a patient's own immune cells to target and destroy cancer cells. Their lead product candidate is for the treatment of melanoma and other solid tumors.
Leadership and Structure
The leadership team includes key executives in research and development, clinical operations, and business development. The company structure is organized around the development and commercialization of TIL therapies.
Top Products and Market Share
Key Offerings
- ITIL-168 (Lifileucel): Lifileucel is Instil Bio's lead product candidate, a tumor-infiltrating lymphocyte (TIL) therapy being developed for the treatment of advanced melanoma. It's currently undergoing clinical trials, and therefore, currently has no market share. Competitors developing similar therapies include Iovance Biotherapeutics (IOVA).
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and the potential for personalized cancer treatments. The industry is characterized by intense research and development, regulatory hurdles, and high costs.
Positioning
Instil Bio is positioned as a player in the cell therapy space, specifically focused on TIL therapies for solid tumors. Their competitive advantage lies in their expertise in TIL manufacturing and clinical development.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is projected to reach billions of dollars. Instil Bio is positioned to capture a portion of this market with its TIL therapies, primarily targeting melanoma and other solid tumors. Precise TAM and expected share figures require proprietary market analysis.
Upturn SWOT Analysis
Strengths
- Specialized TIL expertise
- Novel cell therapy platform
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited commercialized products
- High cash burn rate
- Reliance on clinical trial success
- Manufacturing complexities of TIL therapies
Opportunities
- Expansion of TIL therapies to new indications
- Partnerships with pharmaceutical companies
- Advancements in cell therapy manufacturing technologies
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- IOVA
- CRBU
- NK
- ZYME
Competitive Landscape
Instil Bio operates in a competitive landscape with other cell therapy companies. Their advantage lies in their TIL expertise, but they face competition from larger, more established companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the expansion of the company's research and development pipeline and the progression of clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of TIL therapies. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include the advancement of ITIL-168 (Lifileucel) in clinical trials and the expansion of the company's manufacturing capabilities.
Summary
Instil Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies, particularly TILs, for solid tumors. Their future success hinges on positive clinical trial outcomes and efficient manufacturing. The company faces competition and regulatory hurdles but has potential for growth in the expanding cell therapy market. Financial health depends on continued funding and achieving commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Instil Bio Inc. SEC Filings (10-K, 10-Q), Press Releases, Investor Presentations, Third-party Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may not be entirely accurate or complete. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Instil Bio Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-03-19 | Chairman & CEO Mr. Bronson Crouch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://instilbio.com |
Full time employees 14 | Website https://instilbio.com | ||
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.